Form 4: Teva Pharmaceutical Industries EVP, CFO Eliyahu Sharon Kalif Reports Share Transactions
SEC Form 4
Eliyahu Sharon Kalif, EVP and CFO of Teva Pharmaceutical Industries, reports the acquisition and disposal of ordinary shares and restricted share units.
Summary
- On March 3, 2024, Eliyahu Sharon Kalif acquired 49,800 ordinary shares through the vesting of restricted share units and disposed of 49,800 ordinary shares.
- Following these transactions, Kalif directly owns 174,022 ordinary shares.
- On March 4, 2024, Kalif acquired 33,512 ordinary shares through the vesting of restricted share units and disposed of 33,512 ordinary shares.
- Following these transactions, Kalif directly owns 207,534 ordinary shares.
- On March 4, 2024, Kalif was granted 93,005 restricted share units which vest annually from March 4, 2025 to March 4, 2028.
- Following these transactions, Kalif directly owns 93,005 restricted share units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing share transactions, and does not inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of share transactions by a company executive, which is a common practice in publicly traded companies to ensure transparency and compliance with securities regulations.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership of shares by a key executive.
Key Dates
| Date | Description |
|---|---|
| March 3, 2023 | Restricted share units were granted, vesting annually from March 3, 2024 to March 3, 2027. |
| March 4, 2022 | Restricted share units were granted, vesting annually from March 4, 2023 to March 4, 2026. |
| March 3, 2024 | Acquisition and disposal of 49,800 ordinary shares; vesting of restricted share units. |
| March 4, 2024 | Acquisition and disposal of 33,512 ordinary shares; vesting of restricted share units; grant of 93,005 restricted share units. |
| March 5, 2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.